COVID-19 impacts the expression of molecular markers associated with neuropsychiatric disorders

• Autor(a) principal: Quincozes-Santos, André
• Data de Publicação: 2021
• Outros Autores: Rosa, Rafael Lopes da, Cagnini, Emanuela Fernanda Tureta, Bobermin, Larissa Daniele, Oliveira, Markus Berger, Guimaraes, Jorge Almeida, Santi, Lucélia, Silva, Walter Orlando Beys da
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/219463
• topic: Infecções por coronavirus; Transtornos mentais; Marcadores genéticos; COVID-19; Neuropsychiatric disorders; Molecular markers; Elite genes; Neuroinflammation

Coronavirus disease 2019 (COVID-19) was initially characterized due to its impacts on the respiratory system; however, many recent studies have indicated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly affects the brain. COVID-19 can cause neurological complications, probably caused by the induction of a cytokine storm, since there is no evidence of neurotropism by SARS-CoV-2. In line with this, the COVID-19 outbreak could accelerate the progression or affect the clinical outcomes of neuropsychiatric conditions. Thus, we analyzed differential gene expression datasets for clinical samples of COVID-19 patients and identified 171 genes that are associated with the pathophysiology of the following neuropsychiatric disorders: alcohol dependence, autism, bipolar disorder, depression, panic disorder, schizophrenia, and sleep disorder. Several of the genes identified are associated with causing some of these conditions (classified as elite genes). Among these elite genes, 9 were found for schizophrenia, 6 for autism, 3 for depression/major depressive disorder, and 2 for alcohol dependence. The patients with the neuropsychiatric conditions associated with the genes identified may require special attention as COVID-19 can deteriorate or accelerate neurochemical dysfunctions, thereby aggravating clinical outcomes.